AveXis (AVXS): Raising PT After Gene Editing Summit Points To Improvements - Jefferies
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of AveXis (NASDAQ: AVXS) and increased his price target to $58 from $50 after the company presented at the Jefferies Gene Editing Summit.
Management reiterated their impressive motor milestone data, initially presented at World Muscle however, this was taken one step further as the company disclosed that the patient has come off of permanent ventilation and is recovering well from surgery.
The analyst updated the model for a 30% risk adjustment (lower) for AVXS-101 in SMA Type 1 resulting in the higher price target.
Shares of AveXis closed at $48.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Reiterates Buy on PPG Industries (PPG) - PT to $113
- BMO Capital Remains Cautious on Bristol-Myers Squibb (BMY) Despite Decline; PT Lowered to $56
- BMO Capital Raises Price Target on ManpowerGroup (MAN) Following 3Q Surprise
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Management Comments
Related EntitiesJefferies & Co, S1
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!